Recent 8-K filings for ANIX

• February 9, 2026, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  Anixa reports extended survival in ovarian cancer CAR-T trial; regulatory approval for 100x dose escalation

  12 patients treated; 7 lived beyond expected median survival of 3-4 months; one survived 28 months.

• December 12, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Anixa reports final Phase 1 breast cancer vaccine data: 74% immune response, safe, advancing to Phase 2

  Vaccine met all primary endpoints; 74% of participants showed protocol-defined aLA-specific T cell responses.

• November 8, 2024, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Anixa Biosciences presents updated positive Phase 1 data for breast cancer vaccine; Phase 2 planned for 2025

  Phase 1 trial of alpha-lactalbumin vaccine updated at SITC; data continue positive trend across 3 cohorts.

• May 8, 2024, 7:59 PM ET other material materiality 0.60 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  Anixa expands Cleveland Clinic joint development to develop additional cancer vaccines

  Anixa and Cleveland Clinic entered Joint Development and Option Agreement to develop vaccines for multiple cancers.

Materiality & sentiment trend

Max materiality 0.80 · Median 0.60 · Most common event other_material

4 positive 0 negative 3 neutral

source · ANIX on sec.gov